RE: Certainly a STS treatment but may be much much more ? 🤔19 Sep 2023 10:39
This from the RNS seems an indication of fast track approval for AVA6000 to be used in STS and Dr Tap could have been key in convincing the FDA “the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA)”.
It doesn’t rule out using it for other cancer types but it may be about to replace dox